Equities research analysts expect that Sientra Inc (NASDAQ:SIEN) will announce earnings per share of ($0.68) for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Sientra’s earnings, with the highest EPS estimate coming in at ($0.61) and the lowest estimate coming in at ($0.74). Sientra reported earnings per share of ($0.92) during the same quarter last year, which indicates a positive year-over-year growth rate of 26.1%. The firm is expected to report its next earnings report on Tuesday, March 12th.
On average, analysts expect that Sientra will report full year earnings of ($3.05) per share for the current fiscal year, with EPS estimates ranging from ($3.12) to ($2.98). For the next financial year, analysts forecast that the firm will post earnings of ($2.48) per share, with EPS estimates ranging from ($2.64) to ($2.34). Zacks’ EPS averages are an average based on a survey of analysts that cover Sientra.
Sientra (NASDAQ:SIEN) last announced its earnings results on Tuesday, November 6th. The medical instruments supplier reported ($0.72) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.05). Sientra had a negative return on equity of 132.84% and a negative net margin of 126.03%. The business had revenue of $16.90 million for the quarter, compared to analyst estimates of $16.66 million. During the same quarter in the previous year, the company earned ($0.74) EPS. The business’s revenue for the quarter was up 72.4% on a year-over-year basis.
Shares of NASDAQ:SIEN opened at $17.29 on Tuesday. Sientra has a 12-month low of $8.79 and a 12-month high of $26.79. The company has a market cap of $486.19 million, a price-to-earnings ratio of -6.13 and a beta of -0.41. The company has a current ratio of 2.77, a quick ratio of 2.34 and a debt-to-equity ratio of 0.36.
In related news, Director Timothy Haines sold 89,651 shares of the stock in a transaction that occurred on Tuesday, November 6th. The shares were sold at an average price of $21.56, for a total transaction of $1,932,875.56. Following the sale, the director now owns 37,662 shares in the company, valued at approximately $811,992.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 31.00% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of SIEN. Commonwealth Equity Services LLC acquired a new stake in shares of Sientra during the 2nd quarter worth approximately $210,000. Sei Investments Co. lifted its stake in Sientra by 1,701.3% in the 2nd quarter. Sei Investments Co. now owns 55,103 shares of the medical instruments supplier’s stock valued at $1,076,000 after purchasing an additional 52,044 shares during the last quarter. EAM Investors LLC bought a new position in Sientra in the 2nd quarter valued at approximately $4,428,000. EAM Global Investors LLC bought a new position in Sientra in the 2nd quarter valued at approximately $1,198,000. Finally, Rhumbline Advisers lifted its stake in Sientra by 55.6% in the 2nd quarter. Rhumbline Advisers now owns 21,621 shares of the medical instruments supplier’s stock valued at $422,000 after purchasing an additional 7,725 shares during the last quarter. Institutional investors and hedge funds own 87.01% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: What is Depreciation?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.